Role of cyclooxygenase inhibitors for the prevention of colorectal cancer

Gastroenterology Clinics of North America

Volumn 30, Issue 4, 2001, Pages 1001-1010

  Stack, Elizabeth ^a,c   DuBois, Raymond N ^a,b,c  

^a Department of Medicine ^*  (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID; CYCLOOXYGENASE 2; NONSTEROID ANTIINFLAMMATORY AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE INHIBITOR;

ADENOMATOUS POLYP; CANCER PREVENTION; COLORECTAL CANCER; DIGESTIVE SYSTEM INJURY; ENZYME ACTIVITY; HUMAN; PROSTAGLANDIN SYNTHESIS INHIBITION; REVIEW;

EID: 0035198106     PISSN: 08898553     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8553(05)70225-9     Document Type: Article

References (56)

1. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis
2. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis
3. Prostaglandin receptors: Their role in regulating renal function
4. Localization of cyclooxygenase-2 in human sporadic colorectal adenoma
5. COX-1 and COX-2 tissue expression: Implications and predictions
6. 2 is a mediator of cyclooxygenase-2-dependent endothelial migration and angiogenesis
7. Distribution of prostaglandin E receptors in the rat gastrointestinal tract
8. Cyclooxygenase in biology and disease
9. Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors
10. Cloning and characterization of a growth factor-inducible cyclooxygenase gene from rat intestinal epithelial cells
11. Up-regulation of cyclooxygenase-2 gene expression in human colorectal adenomas and adenocarcinomas
12. Role of intestinal epithelial cells in the host secretory response to infection by invasive bacteria: Bacterial entry induces epithelial prostaglandin h synthase-2 expression and prostaglandin E2 and F2alpha production
13. The peroxisome proliferator-activated receptors: Ligands and activators
14. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis
15. The role of nonsteroidal antiinflammatory drugs in colorectal cancer prevention
16. Aspirin and the risk of colorectal cancer in women
17. PPARδ is an APC-regulated target of nonsteroidal anti-inflammatory drugs
18. Prostaglandin synthase 2
19. Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas, and selective toxicity against Apc mutant embryos
20. Min mouse model by the nonsteroidal anti-inflammatory drug piroxicam
21. Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer
22. Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor
23. Aspirin and the potential role of prostaglandins in colon cancer
24. Anti-inflammatories inhibit cancer growth - But how?
25. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors
26. Cellular distribution of prostanoid EP receptors mRNA in the rat gastrointestinal tract
27. 716 knockout mice by inhibition of prostaglandin endoperoxide synthase-2 (COX-2)
28. Chemoprevention of intestinal polyposis in the Apcdelta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor
29. Genetic disruption of PPARdelta decreases the tumorigenicity of human colon cancer cells
30. Enhancement of intrinsic tumor cell radiosensitivity induced by a selective cyclooxygenase-2 inhibitor
31. Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction
32. Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis
33. APC mutations occur early during colorectal tumorigenesis
34. Chemoprevention of colon cancer by minor dietary constituents and their synthetic analogues
35. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis
36. Expression of cyclooxygenase-1 and -2 in human colorectal cancer
37. Effects of nonsteroidal antiinflammatory drugs on platelet function and systemic hemostasis
38. NSAIDs, gastrointestinal injury and cytoprotection
39. Prostaglandin E2 increases growth and motility of colorectal carcinoma cells
40. Role of cyclooxygenase-2 in the healing of gastric ulcers in rats
41. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: A randomized controlled trial
42. Colorectal cancer and non steroidal anti-inflammatory drugs
43. Use of nonsteroidal anti-inflammatory drugs and incidence of colorectal cancer: A population-based study
44. Differentiation of monocytoid THP-1 cells with phorbol ester induces expression of prostaglandin endoperoxide synthase-1 (COX-1)
45. Prostaglandin endoperoxide synthase: Structure and catalysis
46. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis
47. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase-2
48. Cyclooxygenase regulates angiogenesis induced by colon cancer cells
49. Sulindac for polyposis of the colon
50. Sulindac for polyposis of the colon
51. Inhibitory effect of a prostaglandin E receptor subtype EP(1) selective antagonist, ONO-8713, on development of azoxymethane-induced aberrant crypt foci in mice
52. Comparison of recombinant cyclooxygenase-2 to native isoforms: Aspirin labeling of the active site
53. The role of cyclooxygenases in inflammation, cancer and development
54. Host cyclooxygenase-2 modulates carcinoma growth
55. Prostaglandin endoperoxide synthase: Why two isoforms?
56. Elevated cyclooxygenase-2 levels in Min mouse adenomas